



EXPRESS MAIL #ER926792317US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John Hilfinger et al.

Attorney Docket: TSR-10002/38

Serial No.: 10/706,738

Group Art Unit: 1632

Filed: November 12, 2003

Confirmation No. 7532

For: METHODS AND COMPOSITIONS OF GENE DELIVERY AGENTS  
FOR SYSTEMIC AND LOCAL THERAPY

---

**REQUEST FOR CORRECTED FILING RECEIPT**

Attn. Office of Initial Patent Examination  
Customer Service Center  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Applicant in the above-identified patent application respectfully requests a corrected Filing Receipt to correct inventor's name. Corrections have been made in red ink to the attached Filing Receipt.

If any fees or charges are necessary, please charge them to our Deposit Account No. 07-1180.

If the Examiner has any further questions relating to this application, Applicant's attorney may be reached at (248) 647-6000.

Respectfully submitted,

Date:

January 24, 2005

Avery N. Goldstein

Avery N. Goldstein, Reg. No. 39,204  
Attorney for Applicant  
Gifford, Krass, Groh, Sprinkle,  
Anderson & Citkowski, P.C.  
P.O. Box 7021  
Troy, MI 48007-7021  
(248) 647-6000



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/706,738	11/12/2003	1632	430	TSR-10002/38	7	23	3

CONFIRMATION NO. 7532

25006  
GIFFORD, KRASS, GROH, SPRINKLE  
ANDERSON & CITKOWSKI, PC  
280 N OLD WOODARD AVE  
SUITE 400  
BIRMINGHAM, MI 48009

## UPDATED FILING RECEIPT



\*OC000000014234732\*

Date Mailed: 10/29/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

### Applicant(s)

**BLAKE**

John Hilfinger, Ann Arbor, MI;  
~~Blake~~ Roessler, Ann Arbor, MI;  
Phillip Kish, Ann Arbor, MI;

**Power of Attorney:** The patent practitioners associated with Customer Number **25006**.

### Domestic Priority data as claimed by applicant

This appln claims benefit of 60/425,379 11/12/2002

### Foreign Applications

If Required, Foreign Filing License Granted: 07/22/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/706,738**

Projected Publication Date: 02/03/2005

Non-Publication Request: No

Early Publication Request: No

**RECEIVED**  
OCT 31 2004  
GIFFORD, KRASS, GROH, SPRINKLE,  
ANDERSON & CITKOWSKI, P.C.

**\*\* SMALL ENTITY \*\***

**Title**

Methods and compositions of gene delivery agents for systemic and local therapy

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).